Genscript Biotech Corp (STU:G51)

Full Year 2024 Genscript Biotech Corp Earnings Call Transcript

Mar 11, 2025 / 11:15 PM GMT

Release Date Price: €1.56 (+0.65%)

Transcript

Key Points

Positve

Genscript Biotech Corp (GNNSF) achieved a significant net profit of around $2.9 billion, primarily due to a one-time investment gain from the deconsolidation of Legend Biotech.
The Life Sciences group's revenue grew by 10.2% year over year, driven by strong demand from AI-related applications and antibody drug research.
The company has a robust R&D focus, with 10% of its workforce dedicated to research and development, leading to over 250 patents and more than 480 patents in the application process.
Genscript Biotech Corp (GNNSF) has made significant strides in ESG, joining the United Nations Global Compact and receiving a bronze medal from the Pharmaceutical Supply Chain Initiative.
The protein segment experienced nearly 50% revenue growth, attributed to operational excellence and a proactive marketing strategy.

Negative

Probio's revenue declined by 13.2% year over year, primarily due to a challenging biotech funding environment.
The company faced geopolitical tensions and industry challenges, impacting the first half of 2024.
There was a significant rise in administrative expenses due to the new facility in Hopewell, US, which was not yet fully operational in 2024.
The aggressive market pricing strategy led to a flat gross margin outlook for 2025, despite expected revenue growth.
The deconsolidation of Legend Biotech resulted in a loss being recorded under discontinued operations, impacting the financial statements.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

1548.HK - Genscript Biotech Corp
Full Year 2024 Genscript Biotech Corp Earnings Call
Mar 11, 2025 / 11:15PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to Gencri Biotech 2024 annual results conference call. At this time, all participants are a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone keypad.

You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shinyu Wei, CFO. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.